Literature DB >> 31054042

Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.

F Li1, W He1, R Geng1, X Xie2.   

Abstract

PURPOSE: High expression of ecotropic viral integration site 1 (EVI1) has been associated with a poor prognosis in leukemia patients, but the underlying mechanism remains unclear. Aberrant expression of microRNAs plays critical roles in leukemia development. MiR-9 is a putative potential target of EVI1. We have investigated the regulating mechanism of miR-9 by EVI1 in leukemia cells.
METHODS: We first examined the relationship between miR-9 and EVI1 expression levels in nine leukemia cell lines by RT-PCR. Then we forced high expression of EVI1 in UoCM1 and K562 cells to confirm the downregulation of miR-9 by EVI1. Methylation of the miR-9 promoter region was detected by DNA bisulfite sequencing. We treated the EVI1-overexpressing cells with the hypomethylating agent 5-aza-2'-deoxycytidine (5-AZA) to reverse EVI1-induced hypermethylation of miR-9.
RESULTS: EVI1 and miR-9 expression was negative related. Forced expression of EVI1 downregulated miR-9 by inducing hypermethylation of the miR-9 promoter. 5-AZA reversed high EVI1-induced hypermethylation of the miR-9 promoter and restored the expression of miR-9. 5-AZA induced extensive apoptosis and inhibited proliferation through cell cycle arrest in EVI1-overexpressing leukemia cells.
CONCLUSIONS: Our results suggest that EVI1 may be involved in leukemia cell proliferation and apoptosis via the regulation of miR-9 promoter methylation. 5-AZA may represent a promising therapeutic option for EVI1-high leukemia patients.

Entities:  

Keywords:  5-Aza-2′-deoxycytidine; EVI1; Methylation; Myeloid Leukemia; miR-9

Mesh:

Substances:

Year:  2019        PMID: 31054042     DOI: 10.1007/s12094-019-02121-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  28 in total

Review 1.  Gene silencing in cancer in association with promoter hypermethylation.

Authors:  James G Herman; Stephen B Baylin
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

2.  The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development.

Authors:  P R Hoyt; C Bartholomew; A J Davis; K Yutzey; L W Gamer; S S Potter; J N Ihle; M L Mucenski
Journal:  Mech Dev       Date:  1997-07       Impact factor: 1.882

3.  EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.

Authors:  B V Balgobind; S Lugthart; I H Hollink; S T J C M Arentsen-Peters; E R van Wering; S S N de Graaf; D Reinhardt; U Creutzig; G J L Kaspers; E S J M de Bont; J Stary; J Trka; M Zimmermann; H B Beverloo; R Pieters; R Delwel; C M Zwaan; M M van den Heuvel-Eibrink
Journal:  Leukemia       Date:  2010-04-01       Impact factor: 11.528

Review 4.  Epigenetic activation of tumor suppressor microRNAs in human cancer cells.

Authors:  Yoshimasa Saito; Peter A Jones
Journal:  Cell Cycle       Date:  2006-10-01       Impact factor: 4.534

5.  Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.

Authors:  Sanne Lugthart; Stefan Gröschel; H Berna Beverloo; Sabine Kayser; Peter J M Valk; Shama Lydia van Zelderen-Bhola; Gert Jan Ossenkoppele; Edo Vellenga; Eva van den Berg-de Ruiter; Urs Schanz; Gregor Verhoef; Peter Vandenberghe; Augustin Ferrant; Claus-Henning Köhne; Michael Pfreundschuh; Heinz A Horst; Elisabeth Koller; Marie von Lilienfeld-Toal; Martin Bentz; Arnold Ganser; Brigitte Schlegelberger; Martine Jotterand; Jürgen Krauter; Thomas Pabst; Matthias Theobald; Richard F Schlenk; Ruud Delwel; Konstanze Döhner; Bob Löwenberg; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

6.  MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.

Authors:  Kui Nie; Mario Gomez; Pablo Landgraf; Jose-Francisco Garcia; Yifang Liu; Leonard H C Tan; Amy Chadburn; Thomas Tuschl; Daniel M Knowles; Wayne Tam
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

Review 7.  The role of EVI1 in myeloid malignancies.

Authors:  Carolyn Glass; Michael Wilson; Ruby Gonzalez; Yi Zhang; Archibald S Perkins
Journal:  Blood Cells Mol Dis       Date:  2014-02-01       Impact factor: 3.039

8.  Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis.

Authors:  Vitalyi Senyuk; Yunyuan Zhang; Yang Liu; Ming Ming; Kavitha Premanand; Lan Zhou; Ping Chen; Jianjun Chen; Janet D Rowley; Giuseppina Nucifora; Zhijian Qian
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

Review 9.  MicroRNA and leukemia: tiny molecule, great function.

Authors:  Haifeng Zhao; Donghai Wang; Weiting Du; Dongsheng Gu; Renchi Yang
Journal:  Crit Rev Oncol Hematol       Date:  2009-06-10       Impact factor: 6.312

10.  Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.

Authors:  Katja Haas; Michael Kundi; Wolfgang R Sperr; Harald Esterbauer; Wolf-Dieter Ludwig; Richard Ratei; Elisabeth Koller; Helga Gruener; Cristina Sauerland; Christa Fonatsch; Peter Valent; Rotraud Wieser
Journal:  Genes Chromosomes Cancer       Date:  2008-04       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.